Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Rifamycin SV-MMX in Healthy Volunteers
NCT02969252Phase 1Completed
- Sponsor
- Cosmo Pharmaceuticals
- Start
- Jul 2015
- Primary completion
- Aug 2015
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of rifamycin SV-MMX in traveler's diarrhea (TD), sponsored by Cosmo Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration at Day 1, Time to Maximum Plasma Concentration at Day 1 and 1 more. Started Jul 2015; status: completed.
02
Drugs
rifamycin SV-MMX
03
Conditions
traveler's diarrhea (TD)
Beyond the preview
Go deeper on NCT02969252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02969252.